Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Vaccinex (VCNX) Reports Q4 Revenues Beat Estimates
March 13, 2019 7:24 AM EDTVaccinex (NASDAQ: VCNX) reported Q4 revenue for the quarter came in at $194 thousand versus the consensus estimate of $100 thousand.
The fourth quarter caps a year of significant progress at Vaccinex, during which we transitioned to a publicly-traded company and continued to advance pepinemab in a number of serious and difficult to treat medical conditions, including cancer and... More
